Table 2 Telomerase expression and telomere length in association with clinical and pathological features of breast cancer
Variable | Telomerase expression | P* | Telomere length | P* | ||
|---|---|---|---|---|---|---|
| Â | Low | High | Â | Short | Long | Â |
Telomere length (n = 336) | Â | Â | 0.152 | Â | Â | Â |
Short | 87 (54.7) | 83 (46.9) | Â | Â | Â | Â |
Long | 72 (45.3) | 94 (53.1) | Â | Â | Â | Â |
Disease stage (n = 329) | Â | Â | 0.487 | Â | Â | 0.788 |
I-II | 140 (90.9) | 155 (88.6) | Â | 149 (89.2) | 146 (90.1) | Â |
III-IV | 14 (9.1) | 20 (11.4) | Â | 18 (10.8) | 16 (9.9) | Â |
Tumor grade (n = 332) | Â | Â | 0.292 | Â | Â | 0.300 |
1-2 | 96 (61.2) | 97 (55.4) | Â | 93 (55.4) | 100 (61.0) | Â |
3 | 61 (38.8) | 78 (44.6) | Â | 75 (44.6) | 64 (39.0) | Â |
Tumor size (n = 334) | Â | Â | 0.035 | Â | Â | 0.648 |
T1 | 103 (65.6) | 92 (52.0) | Â | 98 (58.3) | 97 (58.4) | Â |
T2 | 45 (28.7) | 74 (41.8) | Â | 58 (34.5) | 61 (36.8) | Â |
T3 and T4 | 9 (5.7) | 11 (6.2) | Â | 12 (7.1) | 8 (4.8) | Â |
Histological type (n = 335) | Â | Â | 0.094 | Â | Â | 0.252 |
Ductal | 98 (62.0) | 114 (64.4) | Â | 101 (59.8) | 111 (66.9) | Â |
Lobular | 31 (19.6) | 25 (14.1) | Â | 35 (20.7) | 21 (12.7) | Â |
Mix | 19 (12.0) | 15 (8.5) | Â | 17 (9.5) | 18 (10.8) | Â |
Other | 10 (6.4) | 23 (13.0) | Â | 17 (10.1) | 16 (9.6) | Â |
Nodal status (n = 330) | Â | Â | 0.618 | Â | Â | 0.191 |
Negative | 79 (51.0) | 94 (53.7) | Â | 94 (56.0) | 79 (48.8) | Â |
Positive | 76 (49.0) | 81 (46.3) | Â | 74 (44.0) | 83 (51.2) | Â |
ER status (n = 331) | Â | Â | 0.782 | Â | Â | 0.884 |
Negative | 53 (34.0) | 62 (35.4) | Â | 59 (35.1) | 56 (34..4) | Â |
Positive | 103 (66.0) | 113 (64.6) | Â | 109 (64.9) | 107 (65.6) | Â |
PR status (n = 330) | Â | Â | 0.352 | Â | Â | 0.181 |
Negative | 70 (44.9) | 87 (50.0) | Â | 86 (51.2) | 71 (43.8) | Â |
Positive | 86 (55.1) | 87 (50.0) | Â | 82 (48.8) | 91 (56.2) | Â |